secwatch.observer — SEC 8-K summary
======================================

Issuer:     InMed Pharmaceuticals Inc. (INM)
CIK:        0001728328
Form:       8-K
Filed at:   2026-03-23T23:59:59+00:00
Accession:  0001062993-26-001567
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

InMed reports positive INM-901 data in human brain organoid neuroinflammation models
--------------------------------------------------------------------------------

- INM-901 reduced neuroinflammation in 3D human brain organoid models of Alzheimer's disease.
- Dose-dependent reduction of pro-inflammatory markers IL-6 and IL-8 observed in two distinct organoid models.
- Company targets pre-IND meeting with FDA in Q3 2026 and Phase 1 trial start in 2027.
- Prior studies showed reduction of inflammatory biomarkers in in vivo Alzheimer's and ex vivo LPS models.
- Studies conducted with Stem Pharm's proprietary neuro-immune organoid platform.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1728328/000106299326001567/0001062993-26-001567-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1728328/000106299326001567/form8k.htm
  HTML page:      https://secwatch.observer/filing/0001062993-26-001567

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer